obesity
Fourth diet pill makes it to US market
September 11, 2014Manufacturing and Production, Sales and Marketing Contrave, FDA, Orexigen Therapeutics, diet, obesity
Orexigen Therapeutics has gained FDA approval for its new obesity treatment Contrave to help overweight patients reduce their food intake. …
UK health report flags weight and dementia risks
March 28, 2014Sales and Marketing Dame Sally Davies, Public Health England, dementia, obesity
A new Department of Health report suggests that being overweight is now the norm in England – and that deafness …
Alli bottles tampered with in US, drug recalled
March 27, 2014Manufacturing and Production, Sales and Marketing Alli, FDA, GSK, Roche, Xenical, obesity, weight loss
GlaxoSmithKline has admitted that some bottles of its weight-loss drug Alli bought in the US have been tampered with. US …
Government apps tackle alcohol abuse
November 28, 2013Medical Communications alcohol, apps, howe, obesity
The winners of a £2 million government competition to produce apps which will help combat alcohol abuse and weight gain …
Doctor questions FDA’s diet drug approvals
August 23, 2013Research and Development, Sales and Marketing BMJ, Belviq, EMA, FDA, Vivus, diet pills, obesity
Sanofi – aiming for number one in the world’s biggest diabetes market
December 18, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, Sanofi, diabetes, obesity
Sanofi is no different from any other major pharma company in seeing China as the single most important growth market …
Boehringer signs diabetes research deal
September 7, 2012Sales and Marketing Boehringer, diabetes, obesity
Boehringer Ingelheim has signed a four-year research agreement with a top Swiss university to look at the underlying causes of …
FDA clears Arena and Eisai’s obesity drug
June 28, 2012Sales and Marketing Arena, Belviq, Eisai, FDA, Qnexa, Roche, obesity
Eisai and Arena’s Belviq has gained FDA approval, making it the first obesity drug to be approved in over ten …
Obesity drugs vie for approval as FDA panel backs lorcaserin
May 14, 2012Research and Development, Sales and Marketing Arena, Eisai, FDA, Qnexa, lorcaserin, obesity
An FDA panel has recommended Arena’s obesity drug lorcaserin, setting up a showdown with Vivus’ Qnexa. Qnexa was recommended by an FDA panel …
Obesity drug supported by FDA panel
February 23, 2012Sales and Marketing FDA, Qnexa, Vivus, Xenical, obesity
Vivus’ obesity drug Qnexa has been supported by an FDA panel, two years after it was knocked back by the …
Takeda obesity drug falters at phase II
March 18, 2011Research and Development Alli, Amylin, Contrave, Meridia, Qnexa, Takeda, Xenical, lorcaserin, metreleptin, obesity, pramlintide
Yet another investigational drug appears to have faltered on the rocky path to develop anti-obesity treatments. Takeda Pharmaceutical Company and …
New public health body to ‘nudge’ people on healthy living
December 1, 2010NHS reforms, Public Health England, alcohol, obesity, public health, smoking
Plans for a new organiation to oversee public health in England have been unveiled, which will ‘nudge’rather than nag people …
Arena’s obesity treatment lorcaserin rejected by FDA
October 25, 2010Sales and Marketing Arena Pharma, Eisai, FDA, FDA complete response letter, lorcaserin, obesity
A new weight loss drug has been rejected by the FDA because of numerous concerns about side-effects and limited efficacy. …
Abbott withdraws anti-obesity drug amid safety worries
October 11, 2010Sales and Marketing Abbott, Meridia, obesity
Abbott has pulled its anti-obesity drug Meridia in the US after recent trials showed it increased the risk of stroke …
Obesity costs could hit £5bn by 2025
February 12, 2010NHS, obesity
A new review of UK health services has come up with half a dozen ways in which the government should …
Latest content
The evidence bar impacting UK medical cannabis access
Addressing the rheumatic disease diagnostic gap in primary care
